← All trials
NCT06270407
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Feb 21, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Smerud Medical Research DenmarkCollaborator
- Molde University CollegeCollaborator
- University of HelsinkiCollaborator
- University Hospital of North NorwayCollaborator
- Haraldsplass Deaconess HospitalCollaborator
- Sykehuset Innlandet HFCollaborator
- Telemark Hospital TrustCollaborator
- University of BergenCollaborator
- University of StavangerCollaborator
- University of OsloCollaborator
- University of OsloCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.